165 related articles for article (PubMed ID: 9401794)
1. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion.
Takasago T; Peters EE; Graham DI; Masayasu H; Macrae IM
Br J Pharmacol; 1997 Nov; 122(6):1251-6. PubMed ID: 9401794
[TBL] [Abstract][Full Text] [Related]
2. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat.
Dawson DA; Masayasu H; Graham DI; Macrae IM
Neurosci Lett; 1995 Feb; 185(1):65-9. PubMed ID: 7731557
[TBL] [Abstract][Full Text] [Related]
3. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
Lapchak PA; Zivin JA
Stroke; 2003 Aug; 34(8):2013-8. PubMed ID: 12855833
[TBL] [Abstract][Full Text] [Related]
4. Ebselen: prospective therapy for cerebral ischaemia.
Parnham M; Sies H
Expert Opin Investig Drugs; 2000 Mar; 9(3):607-19. PubMed ID: 11060699
[TBL] [Abstract][Full Text] [Related]
5. Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia.
Salom JB; Pérez-Asensio FJ; Burguete MC; Marín N; Pitarch C; Torregrosa G; Romero FJ; Alborch E
Eur J Pharmacol; 2004 Jul; 495(1):55-62. PubMed ID: 15219820
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of ebselen in traumatic brain injury model: involvement of nitric oxide and p38 mitogen-activated protein kinase signalling pathway.
Wei L; Zhang Y; Yang C; Wang Q; Zhuang Z; Sun Z
Clin Exp Pharmacol Physiol; 2014 Feb; 41(2):134-8. PubMed ID: 24131109
[TBL] [Abstract][Full Text] [Related]
7. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia.
Imai H; Masayasu H; Dewar D; Graham DI; Macrae IM
Stroke; 2001 Sep; 32(9):2149-54. PubMed ID: 11546910
[TBL] [Abstract][Full Text] [Related]
8. Effects of ebselen on ischemia/reperfusion injury in rat brain.
Aras M; Altaş M; Meydan S; Nacar E; Karcıoğlu M; Ulutaş KT; Serarslan Y
Int J Neurosci; 2014 Oct; 124(10):771-6. PubMed ID: 24405262
[TBL] [Abstract][Full Text] [Related]
9. Different dose-dependent effects of ebselen in sciatic nerve ischemia-reperfusion injury in rats.
Ozyigit F; Kucuk A; Akcer S; Tosun M; Kocak FE; Kocak C; Kocak A; Metineren H; Genc O
Bosn J Basic Med Sci; 2015 Aug; 15(4):36-43. PubMed ID: 26614850
[TBL] [Abstract][Full Text] [Related]
10. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group.
Yamaguchi T; Sano K; Takakura K; Saito I; Shinohara Y; Asano T; Yasuhara H
Stroke; 1998 Jan; 29(1):12-7. PubMed ID: 9445321
[TBL] [Abstract][Full Text] [Related]
11. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window.
Sydserff SG; Borelli AR; Green AR; Cross AJ
Br J Pharmacol; 2002 Jan; 135(1):103-12. PubMed ID: 11786485
[TBL] [Abstract][Full Text] [Related]
12. Oral pretreatment with ebselen enhances heat shock protein 72 expression and reduces myocardial infarct size.
Baljinnyam E; Hasebe N; Morihira M; Sumitomo K; Matsusaka T; Fujino T; Fukuzawa J; Ushikubi F; Kikuchi K
Hypertens Res; 2006 Nov; 29(11):905-13. PubMed ID: 17345791
[TBL] [Abstract][Full Text] [Related]
13. Ebselen attenuates oxidative DNA damage and enhances its repair activity in the thalamus after focal cortical infarction in hypertensive rats.
He M; Xing S; Yang B; Zhao L; Hua H; Liang Z; Zhou W; Zeng J; Pei Z
Brain Res; 2007 Nov; 1181():83-92. PubMed ID: 17920569
[TBL] [Abstract][Full Text] [Related]
14. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Green AR; Ashwood T
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):109-18. PubMed ID: 15857295
[TBL] [Abstract][Full Text] [Related]
15. Ebselen reduces autophagic activation and cell death in the ipsilateral thalamus following focal cerebral infarction.
Li Y; Zhang J; Chen L; Xing S; Li J; Zhang Y; Li C; Pei Z; Zeng J
Neurosci Lett; 2015 Jul; 600():206-12. PubMed ID: 26091880
[TBL] [Abstract][Full Text] [Related]
16. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial.
Ogawa A; Yoshimoto T; Kikuchi H; Sano K; Saito I; Yamaguchi T; Yasuhara H
Cerebrovasc Dis; 1999; 9(2):112-8. PubMed ID: 9973655
[TBL] [Abstract][Full Text] [Related]
17. Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury.
Tunc T; Uysal B; Atabek C; Kesik V; Caliskan B; Oztas E; Ersoz N; Oter S; Guven A
J Surg Res; 2009 Aug; 155(2):210-6. PubMed ID: 19505699
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia.
Yang Y; Li Q; Shuaib A
Exp Neurol; 2000 May; 163(1):39-45. PubMed ID: 10785442
[TBL] [Abstract][Full Text] [Related]
19. Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates.
Handa Y; Kaneko M; Takeuchi H; Tsuchida A; Kobayashi H; Kubota T
Surg Neurol; 2000 Apr; 53(4):323-9. PubMed ID: 10825515
[TBL] [Abstract][Full Text] [Related]
20. Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats.
Johshita H; Sasaki T; Matsui T; Hanamura T; Masayasu H; Asano T; Takakura K
Acta Neurochir Suppl (Wien); 1990; 51():239-41. PubMed ID: 2089906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
